8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 12, 2026·SEC
Stryker Corporation(SYK)Earnings, Financials & Key Ratios
SYK•NYSE
36.6× P/E·Price updated Jun 19, 2026
AboutStryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.Show more
- Revenue$25.12B+11.2%
- EBITDA$6.08B-0.5%
- Net Income$3.25B+8.5%
- EPS (Diluted)8.40+8.2%
- Gross Margin63.96%+3.4%
- EBITDA Margin24.22%-10.5%
- Operating Margin19.47%-13.1%
- Net Margin12.92%-2.4%
- ROE15.08%-1.2%
SYK Key Insights
Stryker Corporation (SYK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 15.2%
- ✓FCF machine: 17.1% free cash flow margin
- ✓16 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.8%
- ✓Good 3Y average ROE of 16.1%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SYK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SYK Price & Volume
Stryker Corporation (SYK) stock price & volume — 10-year historical chart
Loading chart...
SYK Growth Metrics
Stryker Corporation (SYK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.71%
5 Years11.84%
3 Years10.83%
TTM11.16%
Profit CAGR
10 Years8.47%
5 Years15.21%
3 Years11.24%
TTM8.45%
EPS CAGR
10 Years8.31%
5 Years14.87%
3 Years10.83%
TTM8.25%
Return on Capital
10 Years13.83%
5 Years13.33%
3 Years13.89%
Last Year12.97%
SYK Recent Earnings
Stryker Corporation (SYK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$2.60-12.8%
$2.98
Rev
$6.0B-5.0%
$6.3B
Q1 2026
Jan 29, 2026Metric
Actual
Est
EPS
$4.47+1.6%
$4.40
Rev
$7.2B+0.7%
$7.1B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$3.19+1.9%
$3.13
Rev
$6.1B+0.2%
$6.0B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$3.13+2.0%
$3.07
Rev
$6.0B+1.4%
$5.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $2.60vs $2.98-12.8% | $6.0Bvs $6.3B-5.0% |
| Q1 2026 | Jan 29, 2026 | $4.47vs $4.40+1.6% | $7.2Bvs $7.1B+0.7% |
| Q4 2025 | Oct 30, 2025 | $3.19vs $3.13+1.9% | $6.1Bvs $6.0B+0.2% |
| Q3 2025 | Jul 31, 2025 | $3.13vs $3.07+2.0% | $6.0Bvs $5.9B+1.4% |
Based on last 12 quarters of dataView full earnings history →
SYK Peer Comparison
Stryker Corporation (SYK) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 EW | 50.37B | 87.36 | 47.74 | 11.55% | 17.64% | 10.35% | 0.07 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 SNN | 12.77B | 30.08 | 20.89 | 6.34% | 6.88% | 15.06% | 0.63 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 |
Compare SYK vs Peers
Stryker Corporation (SYK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SYK Income Statement
Stryker Corporation (SYK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 12.44B | 13.6B | 14.88B | 14.35B | 17.11B | 18.45B | 20.5B | 22.59B | 25.12B |
Revenue Growth % | 9.88% | 9.3% | 9.43% | -3.58% | 19.21% | 7.84% | 11.11% | 10.23% | 11.16% |
Cost of Goods Sold | 4.54B | 5B | 5.5B | 5.6B | 6.4B | 7.41B | 8B | 8.62B | 9.05B |
COGS % of Revenue | 36.49% | 36.77% | 36.97% | 39.01% | 37.4% | 40.16% | 39.05% | 38.13% | 36.04% |
Gross Profit | 7.9B▲ 0% | 8.6B▲ 8.8% | 9.38B▲ 9.1% | 8.75B▼ 6.7% | 10.71B▲ 22.3% | 11.04B▲ 3.1% | 12.49B▲ 13.2% | 13.98B▲ 11.9% | 16.07B▲ 14.9% |
Gross Margin % | 63.51% | 63.23% | 63.03% | 60.99% | 62.6% | 59.84% | 60.95% | 61.87% | 63.96% |
Gross Profit Growth % | 9.07% | 8.82% | 9.09% | -6.7% | 22.35% | 3.09% | 13.17% | 11.89% | 14.91% |
Operating Expenses | 5.14B | 5.5B | 5.99B | 5.72B | 6.95B | 7.31B | 8.21B | 8.92B | 11.18B |
OpEx % of Revenue | 41.27% | 40.41% | 40.27% | 39.89% | 40.6% | 39.6% | 40.07% | 39.47% | 44.5% |
Selling, General & Admin | 4.35B | 4.63B | 5.02B | 4.82B | 5.81B | 6.08B | 6.92B | 7.5B | 8.65B |
SG&A % of Revenue | 34.95% | 34.07% | 33.75% | 33.59% | 33.98% | 32.93% | 33.76% | 33.22% | 34.44% |
Research & Development | 787M | 862M | 971M | 905M | 1.13B | 1.23B | 1.29B | 1.41B | 1.58B |
R&D % of Revenue | 6.32% | 6.34% | 6.52% | 6.31% | 6.62% | 6.67% | 6.31% | 6.26% | 6.3% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 902M |
Operating Income | 2.77B▲ 0% | 3.1B▲ 12.2% | 3.39B▲ 9.1% | 3.03B▼ 10.6% | 3.76B▲ 24.3% | 3.73B▼ 0.8% | 4.28B▲ 14.6% | 5.06B▲ 18.2% | 4.89B▼ 3.4% |
Operating Margin % | 22.24% | 22.82% | 22.76% | 21.1% | 22% | 20.24% | 20.89% | 22.4% | 19.47% |
Operating Income Growth % | 7.37% | 12.18% | 9.15% | -10.63% | 24.27% | -0.77% | 14.65% | 18.22% | -3.4% |
EBITDA | 3.41B | 3.83B | 4.17B | 3.84B | 4.75B | 4.73B | 5.31B | 6.11B | 6.08B |
EBITDA Margin % | 27.39% | 28.14% | 27.99% | 26.76% | 27.78% | 25.65% | 25.9% | 27.05% | 24.22% |
EBITDA Growth % | 9.16% | 12.26% | 8.86% | -7.83% | 23.78% | -0.44% | 12.19% | 15.11% | -0.47% |
D&A (Non-Cash Add-back) | 642M | 723M | 778M | 812M | 990M | 998M | 1.03B | 1.05B | 1.19B |
EBIT | 2.31B | 2.62B | 2.85B | 2.27B | 2.62B | 3.02B | 4.03B | 3.89B | 5.12B |
Net Interest Income | -187M | -145M | -132M | -213M | -269M | -243M | -281M | -257M | -486M |
Interest Income | 60M | 119M | 155M | 102M | 68M | 94M | 75M | 139M | 121M |
Interest Expense | 247M | 264M | 287M | 315M | 337M | 337M | 356M | 396M | 607M |
Other Income/Expense | -704M | -748M | -826M | -1.07B | -1.48B | -1.05B | -608M | -1.57B | -375M |
Pretax Income | 2.06B▲ 0% | 2.36B▲ 14.2% | 2.56B▲ 8.7% | 1.95B▼ 23.7% | 2.28B▲ 16.7% | 2.68B▲ 17.6% | 3.67B▲ 36.9% | 3.49B▼ 4.9% | 4.51B▲ 29.3% |
Pretax Margin % | 16.58% | 17.32% | 17.21% | 13.62% | 13.33% | 14.54% | 17.92% | 15.45% | 17.97% |
Income Tax | 1.04B | -1.2B | 479M | 355M | 287M | 325M | 508M | 499M | 1.27B |
Effective Tax Rate % | 50.56% | -50.81% | 18.7% | 18.17% | 12.58% | 12.11% | 13.83% | 14.29% | 28.09% |
Net Income | 1.02B▲ 0% | 3.55B▲ 248.3% | 2.08B▼ 41.4% | 1.6B▼ 23.2% | 1.99B▲ 24.7% | 2.36B▲ 18.3% | 3.17B▲ 34.2% | 2.99B▼ 5.4% | 3.25B▲ 8.5% |
Net Margin % | 8.2% | 26.12% | 13.99% | 11.14% | 11.66% | 12.78% | 15.44% | 13.25% | 12.92% |
Net Income Growth % | -38.07% | 248.33% | -41.37% | -23.24% | 24.7% | 18.25% | 34.22% | -5.43% | 8.45% |
Net Income (Continuing) | 1.02B | 3.55B | 2.08B | 1.6B | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.68▲ 0% | 9.34▲ 248.5% | 5.48▼ 41.3% | 4.20▼ 23.4% | 5.22▲ 24.3% | 6.17▲ 18.2% | 8.25▲ 33.7% | 7.76▼ 5.9% | 8.40▲ 8.2% |
EPS Growth % | -38.39% | 248.51% | -41.33% | -23.36% | 24.29% | 18.2% | 33.71% | -5.94% | 8.25% |
EPS (Basic) | 2.73 | 9.50 | 5.57 | 4.26 | 5.29 | 6.23 | 8.34 | 7.86 | 8.49 |
Diluted Shares Outstanding | 380.1M | 380.3M | 379.9M | 380.3M | 382.3M | 382.2M | 383.7M | 385.6M | 382.2M |
Basic Shares Outstanding | 374M | 374.1M | 374M | 375.5M | 377M | 378.2M | 379.6M | 381M | 382.2M |
Dividend Payout Ratio | 62.35% | 19.79% | 37.35% | 53.97% | 47.64% | 44.57% | 35.99% | 40.73% | 39.56% |
SYK Balance Sheet
Stryker Corporation (SYK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.99B | 9.73B | 11.36B | 9.71B | 10.02B | 10.28B | 12.52B | 14.85B | 14.76B |
Cash & Short-Term Investments | 2.79B | 3.7B | 4.42B | 3.02B | 3.02B | 1.93B | 3.05B | 4.49B | 4.1B |
Cash Only | 2.54B | 3.62B | 4.34B | 2.94B | 2.94B | 1.84B | 2.97B | 3.65B | 4.01B |
Short-Term Investments | 251M | 83M | 88M | 81M | 75M | 84M | 82M | 841M | 89M |
Accounts Receivable | 2.2B | 2.33B | 2.89B | 2.7B | 3.02B | 3.56B | 3.77B | 3.99B | 4.04B |
Days Sales Outstanding | 64.47 | 62.58 | 70.94 | 68.7 | 64.47 | 70.53 | 67.04 | 64.41 | 58.7 |
Inventory | 2.46B | 2.96B | 3.28B | 3.49B | 3.31B | 4B | 4.84B | 4.77B | 5.31B |
Days Inventory Outstanding | 198.13 | 215.67 | 217.73 | 227.82 | 189.03 | 196.81 | 220.85 | 202.26 | 214.14 |
Other Current Assets | 537M | 747M | 760M | 488M | 662M | 787M | 857M | 1.59B | 1.31B |
Total Non-Current Assets | 14.19B | 17.5B | 18.81B | 24.62B | 24.61B | 26.61B | 27.39B | 28.12B | 33.09B |
Property, Plant & Equipment | 1.98B | 2.29B | 2.95B | 3.17B | 3.25B | 3.44B | 3.71B | 3.96B | 3.88B |
Fixed Asset Turnover | 6.30x | 5.94x | 5.04x | 4.52x | 5.26x | 5.36x | 5.53x | 5.70x | 6.48x |
Goodwill | 7.17B | 8.56B | 9.07B | 12.78B | 12.92B | 14.88B | 15.24B | 15.86B | 24.97B |
Intangible Assets | 3.48B | 4.16B | 4.23B | 5.55B | 4.84B | 4.88B | 4.59B | 4.39B | 0 |
Long-Term Investments | 0 | 0 | 0 | 4M | 66M | 90M | 2M | 39M | 0 |
Other Non-Current Assets | 1.3B | 801M | 985M | 1.58B | 1.78B | 1.9B | 2.18B | 2.13B | 3.14B |
Total Assets | 22.18B▲ 0% | 27.23B▲ 22.7% | 30.17B▲ 10.8% | 34.33B▲ 13.8% | 34.63B▲ 0.9% | 36.88B▲ 6.5% | 39.91B▲ 8.2% | 42.97B▲ 7.7% | 47.84B▲ 11.3% |
Asset Turnover | 0.56x | 0.50x | 0.49x | 0.42x | 0.49x | 0.50x | 0.51x | 0.53x | 0.52x |
Asset Growth % | 8.55% | 22.75% | 10.79% | 13.8% | 0.88% | 6.51% | 8.21% | 7.66% | 11.34% |
Total Current Liabilities | 3.29B | 4.81B | 4.4B | 5.04B | 4.55B | 6.3B | 7.92B | 7.62B | 7.79B |
Accounts Payable | 487M | 646M | 675M | 810M | 1.13B | 1.41B | 1.52B | 1.68B | 0 |
Days Payables Outstanding | 39.14 | 47.15 | 44.78 | 52.81 | 64.4 | 69.61 | 69.18 | 71.14 | - |
Short-Term Debt | 632M | 1.37B | 945M | 870M | 119M | 1.31B | 2.24B | 1.55B | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.39B | 1.71B | 1.65B | 2.23B | 2.02B | 2.14B | 2.3B | 2.44B | 7.79B |
Current Ratio | 2.43x | 2.02x | 2.58x | 1.93x | 2.20x | 1.63x | 1.58x | 1.95x | 1.89x |
Quick Ratio | 1.68x | 1.41x | 1.84x | 1.23x | 1.47x | 1.00x | 0.97x | 1.32x | 1.21x |
Cash Conversion Cycle | 223.46 | 231.11 | 243.89 | 243.7 | 189.11 | 197.73 | 218.71 | 195.53 | - |
Total Non-Current Liabilities | 8.73B | 10.69B | 12.96B | 16.2B | 15.21B | 13.96B | 13.4B | 14.72B | 17.63B |
Long-Term Debt | 6.59B | 8.49B | 10.23B | 13.23B | 12.47B | 11.86B | 10.9B | 12.19B | 14.86B |
Capital Lease Obligations | 0 | 0 | 301M | 325M | 310M | 357M | 356M | 379M | 0 |
Deferred Tax Liabilities | 47M | 54M | 108M | 117M | 68M | 67M | 63M | 82M | 0 |
Other Non-Current Liabilities | 2.1B | 2.15B | 2.32B | 2.53B | 2.35B | 1.68B | 2.08B | 2.07B | 2.77B |
Total Liabilities | 12.22B | 15.5B | 17.36B | 21.25B | 19.75B | 20.27B | 21.32B | 22.34B | 25.42B |
Total Debt | 7.22B | 9.86B | 11.48B | 14.43B | 12.9B | 13.53B | 13.49B | 14.12B | 14.86B |
Net Debt | 4.68B | 6.24B | 7.14B | 11.48B | 9.96B | 11.68B | 10.52B | 10.47B | 10.85B |
Debt / Equity | 0.72x | 0.84x | 0.90x | 1.10x | 0.87x | 0.81x | 0.73x | 0.68x | 0.66x |
Debt / EBITDA | 2.12x | 2.58x | 2.75x | 3.76x | 2.71x | 2.86x | 2.54x | 2.31x | 2.44x |
Net Debt / EBITDA | 1.37x | 1.63x | 1.71x | 2.99x | 2.09x | 2.47x | 1.98x | 1.71x | 1.78x |
Interest Coverage | 9.35x | 9.92x | 9.93x | 7.20x | 7.77x | 8.96x | 11.32x | 9.82x | 8.44x |
Total Equity | 9.98B▲ 0% | 11.73B▲ 17.5% | 12.81B▲ 9.2% | 13.08B▲ 2.2% | 14.88B▲ 13.7% | 16.62B▲ 11.7% | 18.59B▲ 11.9% | 20.63B▲ 11.0% | 22.42B▲ 8.7% |
Equity Growth % | 4.5% | 17.54% | 9.18% | 2.16% | 13.7% | 11.69% | 11.9% | 10.98% | 8.66% |
Book Value per Share | 26.26 | 30.84 | 33.71 | 34.40 | 38.91 | 43.47 | 48.46 | 53.51 | 58.66 |
Total Shareholders' Equity | 9.97B | 11.73B | 12.81B | 13.08B | 14.88B | 16.62B | 18.59B | 20.63B | 22.42B |
Common Stock | 37M | 37M | 37M | 38M | 38M | 38M | 38M | 38M | 0 |
Retained Earnings | 8.99B | 10.77B | 11.75B | 12.46B | 13.48B | 14.77B | 16.77B | 18.53B | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -553M | -631M | -606M | -1.16B | -531M | -221M | -416M | -293M | 0 |
Minority Interest | 14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SYK Cash Flow Statement
Stryker Corporation (SYK) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.56B | 2.61B | 2.19B | 3.28B | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B |
Operating CF Margin % | 12.53% | 19.19% | 14.72% | 22.83% | 19.07% | 14.22% | 18.1% | 18.77% | 20.08% |
Operating CF Growth % | -18.59% | 67.42% | -16.05% | 49.57% | -0.43% | -19.58% | 41.43% | 14.31% | 18.91% |
Net Income | 1.02B | 3.55B | 2.08B | 1.6B | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
Depreciation & Amortization | 642M | 723M | 778M | 812M | 990M | 998M | 1.03B | 1.05B | 1.19B |
Stock-Based Compensation | 113M | 119M | 127M | 142M | 171M | 168M | 205M | 229M | 243M |
Deferred Taxes | 36M | -1.58B | 126M | 48M | -237M | 58M | -206M | -370M | 392M |
Other Non-Cash Items | -149M | 1.46B | -253M | -190M | 66M | -226M | 19M | 1.02B | 343M |
Working Capital Changes | -103M | -1.67B | -670M | 866M | 279M | -732M | -500M | -683M | -373M |
Change in Receivables | -162M | -60M | -563M | 354M | -377M | -579M | -175M | -321M | 127M |
Change in Inventory | -320M | -385M | -400M | 27M | -189M | -762M | -797M | -206M | -297M |
Change in Payables | 21M | 116M | 63M | 100M | 329M | 290M | 77M | 192M | 94M |
Cash from Investing | -1.61B | -2.86B | -1.46B | -4.7B | -859M | -2.92B | -962M | -3B | -4.87B |
Capital Expenditures | -598M | -572M | -649M | -487M | -525M | -588M | -575M | -755M | -761M |
CapEx % of Revenue | 4.81% | 4.21% | 4.36% | 3.39% | 3.07% | 3.19% | 2.81% | 3.34% | 3.03% |
Acquisitions | -831M | -2.45B | -802M | -4.22B | -339M | -2.56B | -390M | -1.63B | -4.79B |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -1M | -2M | 1M | 1M | -1M | 39M | 1M | 43M | -60M |
Cash from Financing | -794M | 1.33B | 3M | -11M | -2.37B | -749M | -1.59B | -525M | 113M |
Debt Issued (Net) | 299M | 2.46B | 1.29B | 989M | -1.15B | 472M | -277M | 940M | 1.58B |
Equity Issued (Net) | -230M | -300M | -307M | -110M | -114M | -122M | -155M | -195M | 0 |
Dividends Paid | -636M | -703M | -778M | -863M | -950M | -1.05B | -1.14B | -1.22B | -1.28B |
Share Repurchases | -230M | -300M | -307M | -110M | -114M | -122M | -155M | -195M | 0 |
Other Financing | -227M | -124M | -205M | -27M | -148M | -48M | -23M | -51M | -182M |
Net Change in Cash | -774M▲ 0% | 1.07B▲ 238.8% | 721M▼ 32.9% | -1.39B▼ 293.3% | 1M▲ 100.1% | -1.1B▼ 110100.0% | 1.13B▲ 202.5% | 681M▼ 39.6% | 359M▼ 47.3% |
Free Cash Flow | 961M▲ 0% | 2.04B▲ 112.1% | 1.54B▼ 24.3% | 2.79B▲ 80.9% | 2.74B▼ 1.9% | 2.04B▼ 25.6% | 3.14B▲ 54.0% | 3.49B▲ 11.2% | 4.28B▲ 22.8% |
FCF Margin % | 7.72% | 14.98% | 10.36% | 19.44% | 16% | 11.04% | 15.3% | 15.43% | 17.05% |
FCF Growth % | -32.56% | 112.07% | -24.34% | 80.93% | -1.86% | -25.64% | 54.03% | 11.19% | 22.83% |
FCF per Share | 2.53 | 5.36 | 4.06 | 7.34 | 7.16 | 5.33 | 8.17 | 9.04 | 11.21 |
FCF Conversion (FCF/Net Income) | 1.53x | 0.73x | 1.05x | 2.05x | 1.64x | 1.11x | 1.17x | 1.42x | 1.55x |
Interest Paid | 231M | 248M | 286M | 304M | 325M | 324M | 356M | 396M | 0 |
Taxes Paid | 312M | 539M | 457M | 323M | 622M | 505M | 693M | 989M | 0 |
SYK Key Ratios
Stryker Corporation (SYK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 18.24% | 10.45% | 32.73% | 16.98% | 12.35% | 14.26% | 14.97% | 17.98% | 15.26% | 15.08% |
Return on Invested Capital (ROIC) | 17.35% | 14.93% | 14.27% | 13.4% | 10.2% | 11.43% | 10.54% | 11.18% | 12.61% | 11.39% |
Gross Margin | 63.98% | 63.51% | 63.23% | 63.03% | 60.99% | 62.6% | 59.84% | 60.95% | 61.87% | 63.96% |
Net Margin | 14.54% | 8.2% | 26.12% | 13.99% | 11.14% | 11.66% | 12.78% | 15.44% | 13.25% | 12.92% |
Debt / Equity | 0.72x | 0.72x | 0.84x | 0.90x | 1.10x | 0.87x | 0.81x | 0.73x | 0.68x | 0.66x |
Interest Coverage | 9.43x | 9.35x | 9.92x | 9.93x | 7.20x | 7.77x | 8.96x | 11.32x | 9.82x | 8.44x |
FCF Conversion | 1.16x | 1.53x | 0.73x | 1.05x | 2.05x | 1.64x | 1.11x | 1.17x | 1.42x | 1.55x |
Revenue Growth | 13.86% | 9.88% | 9.3% | 9.43% | -3.58% | 19.21% | 7.84% | 11.11% | 10.23% | 11.16% |
Related:SYK Dividend History·SYK Revenue History·SYK Price History·SYK P/E History·SYK Financial Ratios·SYK Institutional Holders
SYK SEC Filings & Documents
Stryker Corporation (SYK) SEC filings — annual & quarterly reports (10-K, 10-Q)
SYK Frequently Asked Questions
Stryker Corporation (SYK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Stryker Corporation (SYK) reported $25.12B in revenue for fiscal year 2025. This represents a 2660% increase from $910.1M in 1996.
Stryker Corporation (SYK) grew revenue by 11.2% over the past year. This is steady growth.
Yes, Stryker Corporation (SYK) is profitable, generating $3.25B in net income for fiscal year 2025 (12.9% net margin).
Dividend & Returns
Yes, Stryker Corporation (SYK) pays a dividend with a yield of 1.09%. This makes it attractive for income-focused investors.
Stryker Corporation (SYK) has a return on equity (ROE) of 15.1%. This is reasonable for most industries.
Stryker Corporation (SYK) generated $4.28B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.